Amber Therapeutics
Amber Therapeutics develops an adaptive neuromodulation therapy for women with mixed urinary incontinence.
$100M Series A ·
Led by NEA · Source: fundraisingfox.com
Total raised: $200M across 2 sourced rounds
All 2 rounds ↓Signals
Website registeredDec 21, 2020 (5 years old)
About Amber Therapeutics
Its fully implantable Picostim System targets the pudendal nerve to stimulate and sense physiological responses. The therapy is configurable to individual needs and adapts dynamically.
Funding rounds
| Date | Round | Amount | Lead | Source |
|---|---|---|---|---|
| Series A | $100M | fundraisingfox.com | ||
| Series A | $100M | fundraisingfox.com |
Timeline
- Website created
Founders and team
AC
Aidan Crawley Co-founder & CEOLinkedIn · source: amber-tx.comTD
Tim Denison Co-founder & Chief EngineerLinkedIn · source: amber-tx.com
Acquisitions
| Acquired company | Price | Announced |
|---|---|---|
| Not disclosed | Date not given · Yahoo Finance |
Investors
88VC
FF-Prime Capital
FFuture Fifty
IInnovate UK
IIntuitive Ventures
LLightstone Ventures
NNEAlead investor
OOxford Science Enterprises
Companies like Amber Therapeutics
VValencia Technologies$35M · Feb 2025
NNewronika$15.88M Series B+ · Feb 2025
CCyrano TherateuticsSeries B+ · May 2025
CCartography Biosciences$67M Series B+ · Oct 2025
HHotSpot Therapeutics$100M Series B+ · Nov 2021
NNervonik$52.5M Series B+ · Apr 2026
Other companies backed by NEA
DDatabento$100M Series B+ · Nov 2026
BBasalt Health$20M Series A · Oct 2026
PPathos$237M Series B+ · Oct 2026
TTamr$21M Series B+ · Oct 2026
SSpiko Paris, France$90M Series B+ · Oct 2026
AAutomating software development$200M Series B+ · Sep 2026
Sources and API
Every amount links to the page it came from. * Estimated from an accelerator's published standard deal, not a company-specific disclosure. How Recent Funding sources and verifies funding data. The same data as JSON: /api/v1/companies/amber-therapeutics (get a free API key).